Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation

Novel oral anticoagulants in non-valvular atrial fibrillation

(2013) Tatjana S. Potpara et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation

(2013) Pilar Gallego et al.   THROMBOSIS AND HAEMOSTASIS

Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions?

(2013) William O’Neil et al.   THROMBOSIS AND HAEMOSTASIS

General mechanisms of coagulation and targets of anticoagulants (Section I)

(2013) Steen Husted et al.   THROMBOSIS AND HAEMOSTASIS

Vitamin K antagonists in heart disease: Current status and perspectives (Section III)

(2013) Raffaele Caterina et al.   THROMBOSIS AND HAEMOSTASIS

Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation

(2012) Gregory Y.H. Lip et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada

(2012) Michael Sharma et al.   THROMBOSIS AND HAEMOSTASIS

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation

(2012) Jack Ansell et al.   THROMBOSIS AND HAEMOSTASIS

Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: What’s next?

(2012) Svetlana Marx et al.   THROMBOSIS AND HAEMOSTASIS

Indirect comparison studies – are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation

(2012) Torben Larsen et al.   THROMBOSIS AND HAEMOSTASIS

Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis

(2012) L. H. Rasmussen et al.   BMJ-British Medical Journal

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Does Warfarin for Stroke Thromboprophylaxis Protect Against MI in Atrial Fibrillation Patients?

(2010) Gregory Y.H. Lip et al.   AMERICAN JOURNAL OF MEDICINE

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

(2010) Lars Wallentin et al.   LANCET

Newly Identified Events in the RE-LY Trial

(2010) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation

(2008) Yi Wan et al.